Contributions of BatchNumberBede

Contributions by BatchNumberBede, newest first. This list covers edits recorded in the site's change log; the editor's lifetime total of 1,022 edits includes activity predating the current log.

1. 22:16, 8 Jun 2026 (diff | hist) Zhuhai Kerui Biotechnology 14,711 ±0 m label the reception tally as weak, self-selected evidence at this point of use
2. 15:41, 20 May 2026 (diff | hist) Good manufacturing practice 5,123 ±0 m correct the agency abbreviation at first use
3. 12:55, 4 May 2026 (diff | hist) Talk:Batch number 748 +108 /* Inferring volume from sequence numbers */ reply
4. 07:24, 17 Apr 2026 (diff | hist) Blind sampling 8,193 ±0 ce per PP:MOS
5. 14:30, 11 Apr 2026 (diff | hist) Shenzhen Hybio Pharmaceutical 17,496 ±0 ce, tighten prose
6. 22:00, 9 Apr 2026 (diff | hist) Shanghai Sigma-Audley New Material Technology 15,579 ±0 m expand §Operations and documentation practice
7. 20:49, 31 Mar 2026 (diff | hist) Sigma-Aldrich (Shanghai) Trading 18,641 ±0 m rm the adjective — an organisation article describes, it does not praise
8. 10:20, 16 Mar 2026 (diff | hist) Talk:Batch number 400 +163 /* Date-ordering check */ new section
9. 17:23, 11 Mar 2026 (diff | hist) STEP trial programme 5,534 ±0 m add the trial acronym expansion at first use
10. 09:40, 7 Mar 2026 (diff | hist) Janoshik Analytical 5,235 ±0 m give the fields a compendially-complete certificate would carry
11. 02:04, 20 Jan 2026 (diff | hist) Cagrilintide 4,256 ±0 add the structural figure and caption it properly
12. 21:44, 21 Dec 2025 (diff | hist) Shanghai Sigma-Audley New Material Technology 15,359 ±0 m correct the other-designations row — those are trading variants, not subsidiaries
13. 17:15, 28 Nov 2025 (diff | hist) Shenzhen Hybio Pharmaceutical 12,132 +1,064 expand §Corporate identity and history
14. 19:41, 17 Nov 2025 (diff | hist) Flourishglobal Peptide Biotech 12,376 +226 ce, tighten prose
15. 10:49, 5 Nov 2025 (diff | hist) Nantong Guangyuan Chemical 15,114 +473 add the catalogue size and label it self-reported
16. 23:04, 1 Oct 2025 (diff | hist) GLP-1 receptor agonist 11,148 ±0 m add category for the drug class
17. 10:29, 23 Sep 2025 (diff | hist) Shanghai ERP Biotechnology 6,476 +144 correct the trading name — the short code and the legal name are different things
18. 15:22, 3 Sep 2025 (diff | hist) PolyPeptide Group (Hangzhou) 2,650 ±0 state which lines are held in regional stock
19. 18:39, 30 Aug 2025 (diff | hist) SinoPep 8,064 +707 m fix hyphenation per PP:MOS
20. 02:29, 21 Aug 2025 (diff | hist) Qingdao Saber Technology Pharmaceutical 6,613 +1,063 typo
21. 19:43, 30 Jul 2025 (diff | hist) Tianjin Finder Chemical 10,756 +1,137 clarify that no manufacturing or marketing authorisation is claimed or established
22. 23:00, 26 Jul 2025 (diff | hist) SinoPep 4,983 +33 m add the catalogue size and label it self-reported
23. 12:21, 20 Jul 2025 (diff | hist) SinoPep 4,950 +193 m split overlong sentence
24. 19:35, 29 Jun 2025 (diff | hist) Hubei Jianxiang Bioscience 7,008 +899 m ce
25. 22:44, 27 Jun 2025 (diff | hist) VendorInvestigate 4,918 ±0 m state that the report identifies the sample, not the shipment
26. 23:26, 17 Jun 2025 (diff | hist) Shanghai Wibson Biotechnology 8,222 +124 m de-orphan
27. 09:05, 27 May 2025 (diff | hist) WuXi TIDES 11,615 +271 add the transit window each regional warehouse serves
28. 07:48, 2 May 2025 (diff | hist) Chain of custody 4,085 ±0 m add the note on how to request a batch record rather than a certificate
29. 18:59, 23 Apr 2025 (diff | hist) Sigma-Aldrich (Shanghai) Trading 2,925 +988 rm the discount code added by an anonymous editor
30. 12:04, 17 Apr 2025 (diff | hist) Shanghai Sigma-Audley New Material Technology 8,293 +770 m add the note that self-published material is usable only for what it states about itself
31. 02:05, 28 Feb 2025 (diff | hist) Guangzhou JEEP Biotechnology 9,660 +839 m add the research-use-only statement to the lead rather than only the footer
32. 03:59, 17 Feb 2025 (diff | hist) Limit of detection 3,971 ±0 add the plate-count expression and define its terms
33. 18:36, 7 Feb 2025 (diff | hist) Chinese Peptide Company 9,245 +93 add the registered legal name exactly as it appears in the registry record
34. 05:03, 23 Jan 2025 (diff | hist) Blind sampling 4,974 +153 add the second-opinion point: two services, one lot, is a stronger record
35. 11:23, 6 Jan 2025 (diff | hist) Underfilling 2,383 ±0 m clarify that agreement between certificate and report is a weak finding
36. 21:41, 27 Dec 2024 (diff | hist) Dose escalation schedule 2,870 +122 add the preservative point: unpreserved diluent changes the interval
37. 08:37, 30 Oct 2024 (diff | hist) VendorInvestigate 2,850 +26 m split §What a report shows from §What it does not
38. 16:15, 8 Oct 2024 (diff | hist) Chain of custody 2,673 +259 clarify that a QR code on a certificate proves issuance, not content
39. 06:04, 24 Sep 2024 (diff | hist) Chain of custody 2,414 ±0 expand §Why it is usually absent
40. 04:13, 22 Sep 2024 (diff | hist) Certificate of analysis 3,486 +614 m give the fields a compendially-complete certificate would carry
41. 19:35, 16 Sep 2024 (diff | hist) Wuhan Wansheng Biotechnology 5,546 +344 copyedit
42. 09:00, 9 Sep 2024 (diff | hist) Hunan Aslsen Technology 1,705 +1,705 N create organisation article per PP:VN
43. 04:48, 21 Aug 2024 (diff | hist) PeptideMeter 2,054 +878 clarify that agreement between certificate and report is a weak finding
44. 21:05, 14 Aug 2024 (diff | hist) Semaglutide 4,803 +891 rm the equipotency claim — the cited paper does not make it
45. 17:53, 2 Aug 2024 (diff | hist) Medutest 2,091 +2,091 N start article on the testing subject
46. 20:52, 30 Jul 2024 (diff | hist) GL Biochem (Shanghai) 3,584 +747 correct the regional-warehouse list — six sites, not five
47. 22:51, 26 Jun 2024 (diff | hist) Third-party testing 1,439 +1,439 N start article on the testing subject
48. 09:00, 12 Jun 2024 (diff | hist) Incretin effect 1,841 +1,841 N new article: incretin physiology, expansion welcome